Merck Canada Inc.

Meetings over time

• May 20251 meetingRitu Banerjee, Rodrigo Arancibia
  May 2025: 1 meeting, with Ritu Banerjee, Rodrigo Arancibia
• Jun 20252 meetingsJay Allen, Christopher Rose, Pamela Aung-Thin, Ed Morgan, david k lee
  Jun 2025: 2 meetings, with Jay Allen, Christopher Rose, Pamela Aung-Thin, Ed Morgan, david k lee
• Jul 20251 meetingManuela Tomic
  Jul 2025: 1 meeting, with Manuela Tomic
• Aug 20253 meetingsMatthew Hall, Rodrigo Arancibia, Miro Froehlich, Galen Richardson
  Aug 2025: 3 meetings, with Matthew Hall, Rodrigo Arancibia, Miro Froehlich, Galen Richardson
• Sep 20253 meetingsMackenzy Metcalfe, David K Lee, Pamela Aung-Thin, Klara Hupel, Michael Paramathasan
  Sep 2025: 3 meetings, with Mackenzy Metcalfe, David K Lee, Pamela Aung-Thin, Klara Hupel, Michael Paramathasan
• Oct 20257 meetingsDavid K Lee, Maggie Chi, David McFarlane, Karina Gould, Jade Mallette
  Oct 2025: 7 meetings, with David K Lee, Maggie Chi, David McFarlane, Karina Gould, Jade Mallette
• Nov 20252 meetingsJocelyne Voisin, Daniel MacDonald, Mark Schaan, Rodrigo Arancibia
  Nov 2025: 2 meetings, with Jocelyne Voisin, Daniel MacDonald, Mark Schaan, Rodrigo Arancibia
• Dec 20254 meetingsSandenga Yeba, Justine Frame, Annahat Kochhar, Hosai Zurmati Halim, Elizabeth Wong
  Dec 2025: 4 meetings, with Sandenga Yeba, Justine Frame, Annahat Kochhar, Hosai Zurmati Halim, Elizabeth Wong
• Jan 20262 meetingsMartin Moen, Loris Mirella, Gabrielle Dolgoy, David Norris, David K Lee
  Jan 2026: 2 meetings, with Martin Moen, Loris Mirella, Gabrielle Dolgoy, David Norris, David K Lee
• Feb 20263 meetingsChanel Sterie, Kabisan Thanendran, Dominic LeBlanc, Karim Bardeesy, Janice Charette
  Feb 2026: 3 meetings, with Chanel Sterie, Kabisan Thanendran, Dominic LeBlanc, Karim Bardeesy, Janice Charette
• Mar 20264 meetingsJustine Frame, Ritu Banerjee, Rodrigo Arancibia, Manuela Tomic, Caroline Menard
  Mar 2026: 4 meetings, with Justine Frame, Ritu Banerjee, Rodrigo Arancibia, Manuela Tomic, Caroline Menard
• Apr 20268 meetingsSandenga Yeba, Ritu Banerjee, Maggie Chi, Elizabeth Wong, Annahat Kochhar
  Apr 2026: 8 meetings, with Sandenga Yeba, Ritu Banerjee, Maggie Chi, Elizabeth Wong, Annahat Kochhar
• May 20263 meetingsMark Wiseman, Carlos Vanderloo, Shalene Curtis-Micallef, Ali Ehsassi
  May 2026: 3 meetings, with Mark Wiseman, Carlos Vanderloo, Shalene Curtis-Micallef, Ali Ehsassi
• Jun 20268 meetingsMélanie Joly, Udita Samuel, Manuela Tomic, Martin Moen, Chloe Hanes
  Jun 2026: 8 meetings, with Mélanie Joly, Udita Samuel, Manuela Tomic, Martin Moen, Chloe Hanes
• Jul 20261 meetingKayla Slobodnik, Kaitlyn Pritchard
  Jul 2026: 1 meeting, with Kayla Slobodnik, Kaitlyn Pritchard

Hover or focus a month to see who was met.

What they lobby about

• Health39
• Research and Development35
• Intellectual Property28
• International Trade28
• International Development27
• Industry14
• Science and Technology11
• Federal-Provincial Relations8
• Economic Development4
• Budget3
• Taxation and Finance3
• National Security/Security2
• Privacy and Access to Information2
• Consumer Issues1

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

The 40 most-met of 85 people named in these filings.

Health Canada (HC) (60) · Innovation, Science and Economic Development Canada (ISED) (35) · Global Affairs Canada (GAC) (17) · House of Commons (16) · Treasury Board Of Canada Secretariat (TBS) (13) · Finance Canada (FIN) (9)

In their own words

• Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).
• Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
• Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.